

Vanda Pharmaceuticals Inc.
Form 4
May 16, 2007

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
Polymeropoulos Mihael Hristos

(Last) (First) (Middle)

9605 MEDICAL CENTER
DRIVE, SUITE 300

(Street)

ROCKVILLE, MD 20850

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading
Symbol

Vanda Pharmaceuticals Inc. [VNDA]

3. Date of Earliest Transaction
(Month/Day/Year)

05/14/2007

4. If Amendment, Date Original
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

☐ Director ☐ 10% Owner
☒ Officer (give title below) ☐ Other (specify
below)

Chief Executive Officer

6. Individual or Joint/Group Filing(Check
Applicable Line)
☒ Form filed by One Reporting Person
☐ Form filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/14/2007 ⁽¹⁾		M	V Amount (A) or (D) Price 10,000 A \$ 0.331	10,000	D	
Common Stock	05/14/2007 ⁽¹⁾		S	71 D \$ 19.23	9,929	D	
Common Stock	05/14/2007 ⁽¹⁾		S	100 D \$ 19.25	9,829	D	
Common Stock	05/14/2007 ⁽¹⁾		S	500 D \$ 19.27	9,329	D	
Common Stock	05/14/2007 ⁽¹⁾		S	500 D \$ 19.28	8,829	D	

Edgar Filing: Vanda Pharmaceuticals Inc. - Form 4

Common Stock	05/14/2007 ⁽¹⁾	S	700	D	\$ 19.3	8,129	D
Common Stock	05/14/2007 ⁽¹⁾	S	800	D	\$ 19.31	7,329	D
Common Stock	05/14/2007 ⁽¹⁾	S	100	D	\$ 19.33	7,229	D
Common Stock	05/14/2007 ⁽¹⁾	S	700	D	\$ 19.34	6,529	D
Common Stock	05/14/2007 ⁽¹⁾	S	100	D	\$ 19.35	6,429	D
Common Stock	05/14/2007 ⁽¹⁾	S	280	D	\$ 19.36	6,149	D
Common Stock	05/14/2007 ⁽¹⁾	S	619	D	\$ 19.38	5,530	D
Common Stock	05/14/2007 ⁽¹⁾	S	1,100	D	\$ 19.4	4,430	D
Common Stock	05/14/2007 ⁽¹⁾	S	100	D	\$ 19.41	4,330	D
Common Stock	05/14/2007 ⁽¹⁾	S	1,520	D	\$ 19.42	2,810	D
Common Stock	05/14/2007 ⁽¹⁾	S	300	D	\$ 19.44	2,510	D
Common Stock	05/14/2007 ⁽¹⁾	S	200	D	\$ 19.45	2,310	D
Common Stock	05/14/2007 ⁽¹⁾	S	200	D	\$ 19.46	2,110	D
Common Stock	05/14/2007 ⁽¹⁾	S	600	D	\$ 19.47	1,510	D
Common Stock	05/14/2007 ⁽¹⁾	S	1,355	D	\$ 19.49	155	D
Common Stock	05/14/2007 ⁽¹⁾	S	155	D	\$ 19.51	0	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: Vanda Pharmaceuticals Inc. - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. D S (I	
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	\$ 0.331	05/14/2007		M	3,108	<u>(2)</u>	05/05/2013	Common Stock	3,108
Employee Stock Option (Right to Buy)	\$ 0.331	05/14/2007		M	6,892	<u>(2)</u>	02/10/2015	Common Stock	6,892

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Polymeropoulos Mihael Hristos 9605 MEDICAL CENTER DRIVE SUITE 300 ROCKVILLE, MD 20850	X		Chief Executive Officer	

Signatures

/s/ Mihael H.
Polymeropoulos

05/16/2007

__Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction was administered pursuant to an authorized 10b5-1 plan.
- (2) Exercisable with respect to 25% of the shares one year after the grant, exercisable with respect to and additional 2.08333% of the aggregate shares each month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.